GlassScriptPhysician profile
Mary C Bethoney
NPI 1790856177
$1,368.05
in general payments reported to CMS, 2019-2025
15 companies · $569 in 2025
The $569 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.40 · 2020: $91.28 · 2021: $188 · 2022: $164 · 2023: $156 · 2024: $178 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $224.24 | 2022-2024 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $201.07 | 2021-2025 | |
| Therapeuticsmd, INC. | $184.15 | 2019-2022 | |
| Astellas Pharma US INC | $154.83 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $121.48 | 2025 | Myfembree |
| Exeltis, USA INC. | $116.71 | 2023-2025 | Slynd |
| Agile Therapeutics, INC. | $97.31 | 2021-2022 | |
| Shield Therapeutics INC | $74.88 | 2024-2025 | |
| Hologic Sales and Service, LLC | $45.29 | 2025 | Thinprep 2000 Processor, Aptima |
| Sage Therapeutics, LLC | $43.07 | 2024-2025 | Zurzuvae |
| Becton, Dickinson and Company | $31.65 | 2024-2025 | Bd Onclarity |
| Lupin INC. | $19.93 | 2020 | |
| Evofem Biosciences, INC. | $18.26 | 2020 | |
| Mylan Pharmaceuticals INC. | $18.25 | 2021 | |
| Coopersurgical, INC. | $16.93 | 2024 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Bethoney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.